Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Significance: Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer by 2030. Advances in therapeutic treatments are urgently required to fight against this fatal disease. Here, elucidation of the metabolic signature of PDAC has identified the low-density lipoprotein receptor (LDLR), which facilitates cholesterol uptake, as a promising therapeutic target. Blocking of LDLR reduces the proliferative and clonogenic potential of PDAC cells and decreases activation of the ERK1/2 survival pathway. Moreover, LDLR silencing sensitizes PDAC cells to chemotherapeutic drugs and potentiates the tumoral regression promoted by chemotherapy. Finally, Ldlr is highly expressed at all stages of human PDAC and expression is associated with an increased risk of PDAC recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The PDAC cells’ reliance on lipid (especially cholesterol metabolism) is among the many resistance mechanisms of the PDAC (Guillaumond et al., 2015)”
From The antitumoral effect of statins in pancreatic ductal adenocarcinoma: a scoping review (2026) · cites this paper as Guillaumond et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ryan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Protein Sensors for Membrane Sterols
Goldstein, J. L., DeBose-Boyd, R. A., & Brown, M. S. (2006) · Cell · doi:10.1016/j.cell.2005.12.022 · Cited by 1,517
Cellular cholesterol trafficking and compartmentalization
Ikonen, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2336 · Cited by 1,462
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 3×
“We used control mice (Ink4a/Arf fl/fl; LSL-KrasG12D) and mice bearing spontaneous PDAC (Pdx1-Cre; Ink4a/Arf fl/fl; LSL-KrasG12D) (14) with histological and clinical features similar to those reported in humans.”
BackgroundInfluentialYue, S., Li, J., Lee, S.-Y., Lee, H. J., Shao, T., Song, B., Cheng, L., Masterson, T. A., Liu, X., Ratliff, T. L., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.019 · Cited by 929
Consequences of cellular cholesterol accumulation: basic concepts and physiological implications
Tabas, I. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16452 · Cited by 598
Consequences of cellular cholesterol accumulation: basic concepts and physiological implications
Tabas, I. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216452 · Cited by 540
Li, Y. C., Park, M. J., Ye, S.-K., Kim, C.-W., & Kim, Y.-N. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050959 · Cited by 536
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219555110 · Cited by 413
Self-citationCholesterol and prostate cancer
Pelton, K., Freeman, M. R., & Solomon, K. R. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.07.006 · Cited by 303
OSBP Is a Cholesterol-Regulated Scaffolding Protein in Control of ERK1/2 Activation
Wang, P.-Y., Weng, J., & Anderson, R. G. W. (2005) · Science · doi:10.1126/science.1107710 · Cited by 288
Lipid rafts: signaling and sorting platforms of cells and their roles in cancer
Staubach, S., & Hanisch, F.-G. (2011) · Expert Review of Proteomics · doi:10.1586/epr.11.2 · Cited by 284
Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma
Montero, J., Morales, A., Llacuna, L., Lluis, J. M., Terrones, O., Basañez, G., Antonsson, B., Prieto, J., García-Ruiz, C., Colell, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6161 · Cited by 276
Pancreatic cancer: Overview of descriptive epidemiology
Bosetti, C., Bertuccio, P., Negri, E., La Vecchia, C., Zeegers, M. P., & Boffetta, P. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.20785 · Cited by 193
Cell cholesterol homeostasis: Mediation by active cholesterol
Steck, T. L., & Lange, Y. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.08.007 · Cited by 139
Hong, J. Y., Nam, E. M., Lee, J., Park, J. O., Lee, S., Song, S.-Y., Choi, S. H., Heo, J. S., Park, S. H., Lim, H. Y., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2328-1 · Cited by 134
Targeting the Ras–ERK pathway in pancreatic adenocarcinoma
Neuzillet, C., Hammel, P. R., Tijeras‐Raballand, A., Couvelard, A., & Raymond, É. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9396-2 · Cited by 108
Oh, H. Y., Lee, E. J., Yoon, S., Chung, B. H., Cho, K. S., & Hong, S. J. (2007) · The Prostate · doi:10.1002/pros.20593 · Cited by 104
A cholesterol‐regulated PP2A/HePTP complex with dual specificity ERK1/2 phosphatase activity
Wang, P.-Y., Liu, P., Weng, J., Sontag, E., & Anderson, R. G. W. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg255 · Cited by 98
Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways
Guillaumond, F., Iovanna, J., & Vasseur, S. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2013.12.019 · Cited by 90
Self-citationTu, Y.-S., Kang, X., Zhou, J., Lv, X., Tang, Y., & Guan, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.09.031 · Cited by 82
Oxysterols in cancer cell proliferation and death
de Weille, J. R., Fabre, C., & Bakalara, N. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.02.029 · Cited by 80
Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines
Tatidis, L., Masquelier, M., & Vitols, S. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01018-3 · Cited by 65
Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Garcia-Ruiz, C., Morales, A., & Fernandez-Checa, J. C. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012800228715 · Cited by 61
Statins: Perspectives in cancer therapeutics
Corcos, L., & Jossic-Corcos, C. L. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.02.002 · Cited by 54
Märten, A., von Lilienfeld‐Toal, M., Büchler, M. W., & Schmidt, J. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31802bff16 · Cited by 51
Unfolding the toxicity of cholesterol
Zhang, K., & Kaufman, R. J. (2003) · Nature Cell Biology · doi:10.1038/ncb0903-769 · Cited by 30
Berisha, S. Z., Hsu, J., Robinet, P., & Smith, J. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065003 · Cited by 28
Fujino, M., Miura, S.-I., Matsuo, Y., Tanigawa, H., Kawamura, A., & Saku, K. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.008 · Cited by 19
Cited by
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
Self-citationBian, X., Liu, R., Meng, Y., Xing, D., Xu, D., & Lu, Z. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201606 · Cited by 983
Lipid metabolism in cancer: New perspectives and emerging mechanisms
Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S.-M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.013 · Cited by 758
The interplay between cell signalling and the mevalonate pathway in cancer
Mullen, P. J., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.76 · Cited by 699
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Metadata
- Authors
- Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., Pinault, M., Guimaraes, C., Nigri, J., Loncle, C., Lavaut, M.-N., Garcia, S., Tailleux, A., Staels, B., Calvo, E., Tomasini, R., Iovanna, J. L., & Vasseur, S.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- INSERM, UMR911, Centre de Recherche en Oncologie Biologique et Oncopharmacologie, F-13385 Marseille, France;
- Université de Tours (FR)
- Inserm (FR)
- Molecular Endocrinology and Oncology Research Center, Quebec, QC, Canada G1V 4G2
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-02-09
- Volume
- 112
- Issue
- 8
- Pages
- 2473-2478
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4345573
- OpenAlex
- W1977773843
- Cited by
- 454
- References
- 31
- Citations by year
- 2026: 31 · 2025: 40 · 2024: 48 · 2023: 55 · 2022: 59 · 2021: 62 · 2020: 47 · 2019: 25 · 2018: 30 · 2017: 24 · 2016: 23 · 2015: 8
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Fondation de France
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, cholesterol absorption, LDL receptor, cancer metabolism, lipid metabolism, desmoplasia, chemosensitization, metabolic therapy, recurrence
- MeSH terms
- Gemcitabine, Adenocarcinoma, Animals, Cell Compartmentation, Cholesterol, Clone Cells, Deoxycytidine, Epithelial Cells, Humans, Lipoproteins, Pancreatic Neoplasms, Phenotype, Prognosis, Receptors, LDL, Up-Regulation, Gene Expression Regulation, Neoplastic, Gene Silencing, MAP Kinase Signaling System, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.